RESUMEN
La búsqueda activa es un instrumento de control de calidad de la vigilancia epidemiológica de rutina, pues permite detectar casos de enfermedades prevenibles por vacunación (EPV) que, por cualquier razón, pueden o no haber sido notificados al sistema. Tradicionalmente, la búsqueda activa se ha implementado de forma individual para documentar la ausencia o presencia de casos de parálisis flácida aguda (PFA), sarampión y rubéola, durante la vigilancia de rutina o ante la presencia de brotes. En este sentido, la búsqueda activa de casos de PFA, sarampión y rubéola es realizada en los establecimientos de salud (búsqueda activa institucional [BAI]), en las comunidades (búsqueda activa comunitaria [BAC]), y en los laboratorios (búsqueda activa por laboratorio [BAL]) a fin de identificar oportunidades para mejorar la sensibilidad del sistema de vigilancia epidemiológica de las EPV. Los casos detectados en la búsqueda activa deben notificarse, investigarse y clasificarse de acuerdo con las definiciones de casos recomendadas para la vigilancia de estas enfermedades. El propósito de esta publicación es brindar orientaciones técnicas e instrumentos de recolección de datos para realizar la búsqueda activa integral de PFA, sarampión y rubéola a nivel institucional (establecimientos de salud) y comunitario. La implementación conjunta de la búsqueda activa para estas tres enfermedades apunta a lograr una sinergia de los recursos humanos y financieros, según las consideraciones específicas de cada enfermedad. La publicación está dirigida a los profesionales de la salud de los niveles nacionales y subnacionales que son responsables de organizar e implementar la búsqueda activa en los establecimientos de salud y la comunidad, incluido el análisis de sus resultados y la elaboración del informe.
Asunto(s)
Sarampión , Rubéola (Sarampión Alemán) , Enfermedades Prevenibles por Vacunación , InmunizaciónAsunto(s)
Granuloma , Trasplante de Células Madre Hematopoyéticas , Virus de la Rubéola , Rubéola (Sarampión Alemán) , Trasplante Homólogo , Humanos , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Rubéola (Sarampión Alemán)/diagnóstico , Granuloma/etiología , Virus de la Rubéola/inmunología , Masculino , Femenino , Adulto , Resultado del TratamientoRESUMEN
BACKGROUND AND PURPOSE: The seroprevalence of antibodies against measles, mumps, and rubella (MMR) was evaluated 17 years following a mass vaccination campaign in individuals aged 2 to 22 years who had received routine immunization but were not eligible for an extended immunization program. METHODS: Samples were acquired from Iran's National Measles Laboratory (NML), with individuals showing positive IgM results excluded. Out of the samples collected in 2020, a random selection of 290 serum samples was chosen, representing individuals between the ages of 2 and 22 years from diverse regions in the country. These samples were subjected to analysis using an enzyme-linked immunosorbent assay (ELISA) to quantify specific IgG antibodies against MMR. RESULTS: The seroprevalence rates of antibodies for measles, mumps, and rubella were determined to be 76.2%, 89.3%, and 76.9%, respectively. Younger age groups exhibited higher seropositivity rates for measles and mumps, whereas the 7- to 11-year-old group demonstrated the highest seropositivity rate for rubella. A reduction in antibody status was observed from younger to older age groups, particularly those aged 17-22. CONCLUSION: The study unveiled suboptimal antibody levels for measles and rubella, highlighting the necessity for further investigation and potential adjustments to future vaccination strategies. Moreover, the decline in antibody status post-vaccination can accumulate in seronegative individuals over time, elevating the risk of outbreaks.
Asunto(s)
Anticuerpos Antivirales , Vacunación Masiva , Vacuna contra el Sarampión-Parotiditis-Rubéola , Sarampión , Paperas , Rubéola (Sarampión Alemán) , Humanos , Niño , Adolescente , Irán/epidemiología , Vacuna contra el Sarampión-Parotiditis-Rubéola/inmunología , Vacuna contra el Sarampión-Parotiditis-Rubéola/administración & dosificación , Preescolar , Anticuerpos Antivirales/sangre , Sarampión/epidemiología , Sarampión/inmunología , Sarampión/prevención & control , Masculino , Femenino , Adulto Joven , Estudios Seroepidemiológicos , Rubéola (Sarampión Alemán)/inmunología , Rubéola (Sarampión Alemán)/epidemiología , Rubéola (Sarampión Alemán)/prevención & control , Paperas/inmunología , Paperas/epidemiología , Paperas/prevención & control , Vacunación Masiva/estadística & datos numéricos , Inmunoglobulina G/sangre , Vacunación/estadística & datos numéricos , Ensayo de Inmunoadsorción EnzimáticaRESUMEN
INTRODUCTION: Since the Syrian Civil War began in 2011, the official number of refugees under temporary protection in Turkiye is reported to be 3,522,036 in 2023. Most of the Syrians living outside the refugee camps have worse conditions in terms of access to healthcare centers and social opportunities, compared to those living in camps. The Sanliurfa province hosts the third highest number of Syrians (370,291) in Turkiye. There are no data about the seroprevalence of Toxoplasma gondii (T. gondii), rubella (rub), or cytomegalovirus (CMV) among Syrian refugees in Sanliurfa. We aimed to investigate the seroprevalence of T. gondii, rub, and CMV infections among female Syrian refugees of reproductive age (15-49 years) living in Sanliurfa province. METHODOLOGY: A cross-sectional study was conducted in different districts of Sanliurfa. A total of 460 households were selected using the probability sampling method. One married female Syrian refugee aged between 15 and 49 years, was chosen in each household, leading to a sample size of 410 female Syrian refugees. The seropositivity of T. gondii, CMV, and rub IgM and IgG in blood samples were analyzed using enzyme immunoassays (Abbott Architect, Illinois, USA). RESULTS: The seropositivity rates of T. gondii, CMV, and rubella IgM and IgG were 4.4% and 59.8%; 3.9%; and 99%; and 1.9%, and 99.5%, respectively. CONCLUSIONS: A screening program should be implemented for T. gondii, CMV, and rub infections for Syrian refugees. Seronegative women should be vaccinated against rub and educated about the transmission and preventive routes of toxoplasmosis and CMV infection.
Asunto(s)
Infecciones por Citomegalovirus , Refugiados , Rubéola (Sarampión Alemán) , Toxoplasmosis , Humanos , Femenino , Refugiados/estadística & datos numéricos , Adulto , Estudios Seroepidemiológicos , Toxoplasmosis/epidemiología , Adolescente , Adulto Joven , Rubéola (Sarampión Alemán)/epidemiología , Siria/epidemiología , Siria/etnología , Persona de Mediana Edad , Estudios Transversales , Infecciones por Citomegalovirus/epidemiología , Turquía/epidemiología , Toxoplasma/inmunología , Anticuerpos Antivirales/sangre , Citomegalovirus/inmunología , Citomegalovirus/aislamiento & purificación , Inmunoglobulina M/sangreRESUMEN
BACKGROUND: Rubella is a contagious viral infection that has garnered significant attention in the field of public health due to its potential consequences, especially during pregnancy. In recent decades, it has been recommended that non-immune women receive immunization during the preconceptional and/or postpartum periods. The goal of this strategy is to prevent primary rubella infection in order to protect pregnant women against congenital rubella syndrome. In November 2022, the WHO's Regional Verification Commission declared the elimination of rubella infection in Italy. In recent years, the main migration flows to Italy have originated from regions where rubella has not yet been eliminated and where no program is in place to achieve this goal. OBJECTIVE: The aim of this study was to retrospectively assess rubella immunity in pregnant women who have attended three delivery centers in Rome over the past three years, from January 2021 to May 2023. METHODS: Data about the rubella serological status of 7937 non-consecutive pregnant women were collected. Univariate analysis was performed to verify any difference between the study groups in terms of age distribution. RESULTS: Anti-rubella IgG antibodies were found in 7224 (91%) women while 713 (9%) were susceptible to rubella (IgG negative), without differences in terms of immunity rate between Italian and non-Italian women. Age analysis showed a statistically significant older age of immune women than receptive women and of Italian immune women than non-Italian immune women. CONCLUSIONS: The National Plan for the Elimination of Measles and Congenital Rubella aimed to achieve a percentage of susceptible women of childbearing age below 5%. These data indicate the relevance of maintaining the recommendation for preconceptional rubella vaccination in Italy.
Asunto(s)
Erradicación de la Enfermedad , Atención Preconceptiva , Vacuna contra la Rubéola , Rubéola (Sarampión Alemán) , Atención Preconceptiva/normas , Rubéola (Sarampión Alemán)/epidemiología , Rubéola (Sarampión Alemán)/prevención & control , Vacuna contra la Rubéola/normas , Anticuerpos Antivirales/sangre , Inmunoglobulina G/sangre , Humanos , Femenino , Embarazo , Adolescente , Adulto Joven , Adulto , Persona de Mediana Edad , Italia/epidemiologíaRESUMEN
BACKGROUND: Measles, mumps, and rubella(MMR) vaccination is critical to measles outbreak responses. However, vaccine reactions and detection of measles vaccine RNA in recently immunized persons may complicate case classification especially in those presenting with another respiratory viral illness. We aim to characterize cases of measles vaccine shedding in recently vaccinated children presenting with respiratory viral symptoms. METHODS: Children who were tested with a multiplex respiratory panel <30 days after receiving MMR were identified. Remnant nasopharyngeal(NP) samples were tested for measles vaccine by PCR. Medical records were reviewed for demographics, presenting symptoms, and test results. RESULTS: From January 2022 to March 2023, 127 NP from children who received MMR were tested. Ninety-six NP were collected after the first dose, of which 33(34.4 %) were positive for vaccine RNA. The median interval between MMR and detection was 11.0 days. Thirty-one NP were collected after the second MMR and 1(3.2 %) was positive; time between the vaccination and detection was 18.9 days. Median cycle threshold(Ct) value of the measles PCR for vaccine shedding was significantly higher than median Ct in children with wild-type infection. CONCLUSION: Shedding of measles vaccine RNA is not uncommon and vaccine RNA can be detected up to 29 days post MMR; the amount of vaccine RNA shedding is low indicated by high Ct values. Clinicians and public health officials should consider performing measles vaccine testing on those testing positive for measles within one month of MMR vaccination, especially if the Ct value is high and definitive epidemiological links are absent.
Asunto(s)
Vacuna contra el Sarampión-Parotiditis-Rubéola , ARN Viral , Vacunación , Esparcimiento de Virus , Humanos , Vacuna contra el Sarampión-Parotiditis-Rubéola/administración & dosificación , Vacuna contra el Sarampión-Parotiditis-Rubéola/inmunología , Femenino , Masculino , ARN Viral/genética , Preescolar , Lactante , Niño , Sarampión/prevención & control , Sarampión/inmunología , Nasofaringe/virología , Paperas/prevención & control , Paperas/inmunología , Rubéola (Sarampión Alemán)/prevención & control , AdolescenteRESUMEN
BACKGROUND AND AIM: Immunity alterations have been observed in bipolar disorder (BD). However, whether serum positivity of antibodies to Toxoplasma gondii (T gondii), rubella, and cytomegalovirus (CMV) shared clinical relevance with BD, remains controversial. This study aimed to investigate this association. METHODS: Antibody seropositivity of IgM and IgG to T gondii, rubella virus, and CMV of females with BD and controls was extracted based on medical records from January 2018 to January 2023. Family history, type of BD, onset age, and psychotic symptom history were also collected. RESULTS: 585 individuals with BD and 800 healthy controls were involved. Individuals with BD revealed a lower positive rate of T gondii IgG in the 10-20 aged group (OR = 0.10), and a higher positive rate of rubella IgG in the 10-20 (OR = 5.44) and 20-30 aged group (OR = 3.15). BD with family history preferred a higher positive rate of T gondii IgG (OR = 24.00). Type-I BD owned a decreased positive rate of rubella IgG (OR = 0.37) and an elevated positive rate of CMV IgG (OR = 2.12) compared to type-II BD, while BD with early onset showed contrast results compared to BD without early onset (Rubella IgG, OR = 2.54; CMV IgG, OR = 0.26). BD with psychotic symptom history displayed a lower positive rate of rubella IgG (OR = 0.50). LIMITATIONS: Absence of male evidence and control of socioeconomic status and environmental exposure. CONCLUSIONS: Differential antibody seropositive rates of T gondii, rubella, and cytomegalovirus in BD were observed.
Asunto(s)
Anticuerpos Antiprotozoarios , Anticuerpos Antivirales , Trastorno Bipolar , Citomegalovirus , Inmunoglobulina G , Inmunoglobulina M , Virus de la Rubéola , Toxoplasma , Humanos , Trastorno Bipolar/inmunología , Trastorno Bipolar/sangre , Femenino , Toxoplasma/inmunología , Adulto , Virus de la Rubéola/inmunología , Citomegalovirus/inmunología , Estudios Transversales , Anticuerpos Antivirales/sangre , Adulto Joven , Inmunoglobulina G/sangre , Anticuerpos Antiprotozoarios/sangre , Adolescente , Persona de Mediana Edad , Inmunoglobulina M/sangre , Niño , Toxoplasmosis/inmunología , Toxoplasmosis/sangre , Rubéola (Sarampión Alemán)/inmunología , Infecciones por Citomegalovirus/inmunologíaAsunto(s)
Vacuna Antisarampión , Sarampión , Agujas , Vacuna contra la Rubéola , Rubéola (Sarampión Alemán) , Niño , Preescolar , Humanos , Inyecciones Subcutáneas , Vacuna contra la Rubéola/administración & dosificación , Vacuna contra la Rubéola/inmunología , Vacuna Antisarampión/administración & dosificación , Vacuna Antisarampión/inmunología , Lactante , Gambia , Pueblo de África Occidental , Ensayos Clínicos Controlados Aleatorios como Asunto , Sarampión/prevención & control , Rubéola (Sarampión Alemán)/prevención & controlRESUMEN
Countries with moderate to high measles-containing vaccine coverage face challenges in reaching the remaining measles zero-dose children. There is growing interest in targeted vaccination activities to reach these children. We developed a framework for prioritizing districts for targeted measles and rubella supplementary immunization activities (SIAs) for Zambia in 2020, incorporating the use of the WHO's Measles Risk Assessment Tool (MRAT) and serosurveys. This framework was used to build a model comparing the cost of vaccinating one zero-dose child under three vaccination scenarios: standard nationwide SIA, targeted subnational SIA informed by MRAT, and targeted subnational SIA informed by both MRAT and measles seroprevalence data. In the last scenario, measles seroprevalence data are acquired via either a community-based serosurvey, residual blood samples from health facilities, or community-based IgG point-of-contact rapid diagnostic testing. The deterministic model found that the standard nationwide SIA is the least cost-efficient strategy at 13.75 USD per zero-dose child vaccinated. Targeted SIA informed by MRAT was the most cost-efficient at 7.63 USD per zero-dose child, assuming that routine immunization is just as effective as subnational SIA in reaching zero-dose children. Under similar conditions, a targeted subnational SIA informed by both MRAT and seroprevalence data resulted in 8.17-8.35 USD per zero-dose child vaccinated, suggesting that use of seroprevalence to inform SIA planning may not be as cost prohibitive as previously thought. Further refinement to the decision framework incorporating additional data may yield strategies to better target the zero-dose population in a financially feasible manner.
Asunto(s)
Vacuna Antisarampión , Sarampión , Humanos , Zambia/epidemiología , Sarampión/prevención & control , Sarampión/epidemiología , Sarampión/economía , Vacuna Antisarampión/economía , Vacuna Antisarampión/administración & dosificación , Vacuna Antisarampión/inmunología , Vacunación/economía , Vacunación/métodos , Estudios Seroepidemiológicos , Análisis Costo-Beneficio , Preescolar , Programas de Inmunización/economía , Lactante , Niño , Rubéola (Sarampión Alemán)/prevención & control , Rubéola (Sarampión Alemán)/epidemiología , Rubéola (Sarampión Alemán)/economíaRESUMEN
Rubella infection during pregnancy can result in miscarriage or infants with a constellation of birth defects known as congenital rubella syndrome (CRS). When coverage is inadequate, rubella vaccination can increase CRS cases by increasing the average age of infection. Thus, the World Health Organisation recommends that countries introducing rubella vaccine be able to vaccinate at least 80% of each birth cohort. Previous studies have focused on national-level analyses and have overlooked sub-national variation in introduction risk. We characterised the sub-national heterogeneity in rubella transmission within Nigeria and modelled local rubella vaccine introduction under different scenarios to refine the set of conditions and strategies required for safe rubella vaccine use. Across Nigeria, the basic reproduction number ranged from 2.6 to 6.2. Consequently, the conditions for safe vaccination varied across states with low-risk areas requiring coverage levels well below 80 %. In high-risk settings, inadequate routine coverage needed to be supplemented by campaigns that allowed for gradual improvements in vaccination coverage over time. Understanding local heterogeneities in both short-term and long-term epidemic dynamics can permit earlier nationwide introduction of rubella vaccination and identify sub-national areas suitable for program monitoring, program improvement and campaign support.
Asunto(s)
Programas de Inmunización , Vacuna contra la Rubéola , Rubéola (Sarampión Alemán) , Cobertura de Vacunación , Humanos , Nigeria/epidemiología , Vacuna contra la Rubéola/administración & dosificación , Vacuna contra la Rubéola/inmunología , Rubéola (Sarampión Alemán)/prevención & control , Rubéola (Sarampión Alemán)/epidemiología , Femenino , Cobertura de Vacunación/estadística & datos numéricos , Vacunación/estadística & datos numéricos , Embarazo , Demografía , Lactante , Adolescente , Síndrome de Rubéola Congénita/prevención & control , Síndrome de Rubéola Congénita/epidemiología , Masculino , Adulto Joven , AdultoRESUMEN
BACKGROUND: Microneedle patches (MNPs) have been ranked as the highest global priority innovation for overcoming immunisation barriers in low-income and middle-income countries. This trial aimed to provide the first data on the tolerability, safety, and immunogenicity of a measles and rubella vaccine (MRV)-MNP in children. METHODS: This single-centre, phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial was conducted in The Gambia. To be eligible, all participants had to be healthy according to prespecified criteria, aged 18-40 years for the adult cohort, 15-18 months for toddlers, or 9-10 months for infants, and to be available for visits throughout the follow-up period. The three age cohorts were randomly assigned in a 2:1 ratio (adults) or 1:1 ratio (toddlers and infants) to receive either an MRV-MNP (Micron Biomedical, Atlanta, GA, USA) and a placebo (0·9% sodium chloride) subcutaneous injection, or a placebo-MNP and an MRV subcutaneous injection (MRV-SC; Serum Institute of India, Pune, India). Unmasked staff ransomly assigned the participants using an online application, and they prepared visually identical preparations of the MRV-MNP or placebo-MNP and MRV-SC or placebo-SC, but were not involved in collecting endpoint data. Staff administering the study interventions, participants, parents, and study staff assessing trial endpoints were masked to treatment allocation. The safety population consists of all vaccinated participants, and analysis was conducted according to route of MRV administration, irrespective of subsequent protocol deviations. The immunogenicity population consisted of all vaccinated participants who had a baseline and day 42 visit result available, and who had no protocol deviations considered to substantially affect the immunogenicity endpoints. Solicited local and systemic adverse events were collected for 14 days following vaccination. Unsolicited adverse events were collected to day 180. Age de-escalation between cohorts was based on the review of the safety data to day 14 by an independent data monitoring committee. Serum neutralising antibodies to measles and rubella were measured at baseline, day 42, and day 180. Analysis was descriptive and included safety events, seroprotection and seroconversion rates, and geometric mean antibody concentrations. The trial was registered with the Pan African Clinical Trials Registry PACTR202008836432905, and is complete. FINDINGS: Recruitment took place between May 18, 2021, and May 27, 2022. 45 adults, 120 toddlers, and 120 infants were randomly allocated and vaccinated. There were no safety concerns in the first 14 days following vaccination in either adults or toddlers, and age de-escalation proceeded accordingly. In infants, 93% (52/56; 95% CI 83·0-97·2) seroconverted to measles and 100% (58/58; 93·8-100) seroconverted to rubella following MRV-MNP administration, while 90% (52/58; 79·2-95·2) and 100% (59/59; 93·9-100) seroconverted to measles and rubella respectively, following MRV-SC. Induration at the MRV-MNP application site was the most frequent local reaction occurring in 46 (77%) of 60 toddlers and 39 (65%) of 60 infants. Related unsolicited adverse events, most commonly discolouration at the application site, were reported in 35 (58%) of 60 toddlers and 57 (95%) of 60 infants that had received the MRV-MNP. All local reactions were mild. There were no related severe or serious adverse events. INTERPRETATION: The safety and immunogenicity data support the accelerated development of the MRV-MNP. FUNDING: Bill & Melinda Gates Foundation.
Asunto(s)
Vacuna Antisarampión , Vacuna contra la Rubéola , Rubéola (Sarampión Alemán) , Humanos , Método Doble Ciego , Gambia , Femenino , Masculino , Vacuna contra la Rubéola/administración & dosificación , Vacuna contra la Rubéola/inmunología , Vacuna contra la Rubéola/efectos adversos , Lactante , Vacuna Antisarampión/administración & dosificación , Vacuna Antisarampión/inmunología , Adulto , Adolescente , Rubéola (Sarampión Alemán)/prevención & control , Adulto Joven , Sarampión/prevención & control , Agujas , Anticuerpos Antivirales/sangreRESUMEN
There is increasing interest in evaluating antibody responses to multiple antigen targets in a single assay. Immunity to measles and rubella are often evaluated together because immunity is provided through combined vaccines and because routine immunization efforts and surveillance for measles and rubella pathogens are combined in many countries. The multiplex bead assay (MBA) also known as the multiplex immunoassay (MIA) described here combines the measurement of measles- and rubella-specific IgG antibodies in serum quantitatively according to international serum standards and has been successfully utilized in integrated serological surveillance.
Asunto(s)
Anticuerpos Antivirales , Inmunoglobulina G , Sarampión , Rubéola (Sarampión Alemán) , Rubéola (Sarampión Alemán)/inmunología , Rubéola (Sarampión Alemán)/epidemiología , Rubéola (Sarampión Alemán)/diagnóstico , Rubéola (Sarampión Alemán)/sangre , Sarampión/inmunología , Sarampión/epidemiología , Sarampión/sangre , Sarampión/diagnóstico , Humanos , Anticuerpos Antivirales/sangre , Anticuerpos Antivirales/inmunología , Inmunoglobulina G/sangre , Inmunoglobulina G/inmunología , Inmunoensayo/métodos , Virus de la Rubéola/inmunología , Virus del Sarampión/inmunología , Pruebas Serológicas/métodosAsunto(s)
Vacuna Antisarampión , Vacuna contra la Rubéola , Rubéola (Sarampión Alemán) , Humanos , Vacuna contra la Rubéola/administración & dosificación , Niño , Vacuna Antisarampión/administración & dosificación , Rubéola (Sarampión Alemán)/prevención & control , Sarampión/prevención & control , AgujasRESUMEN
Rubella virus infection during early pregnancy sometimes causes severe birth defects termed congenital rubella syndrome. Although there are safe and effective live-attenuated vaccines, rubella has only been certified as eliminated in the Americas within the six World Health Organization regions. Rubella remains an endemic disease in many regions, and outbreaks occur wherever population immunity is insufficient. There are two main methods for diagnosis of rubella: detection of anti-rubella IgM antibodies by enzyme immunoassay and detection of the viral genome by real-time RT-PCR. Both of these methods require substantial time and effort. In the present study, a rapid rubella detection assay using real-time fluorescent reverse transcription loop-mediated isothermal amplification with quenching primers was developed. The time required for the new assay was one-half that required for a real-time RT-PCR assay. The assay had 93.6% positive percent agreement and 100% negative percent agreement for clinical specimens compared with the real-time RT-PCR assay. The new assay is considered useful for diagnosis of rubella in areas where rubella is endemic.
Asunto(s)
Cartilla de ADN , Técnicas de Amplificación de Ácido Nucleico , Virus de la Rubéola , Rubéola (Sarampión Alemán) , Virus de la Rubéola/genética , Virus de la Rubéola/aislamiento & purificación , Rubéola (Sarampión Alemán)/diagnóstico , Rubéola (Sarampión Alemán)/virología , Humanos , Técnicas de Amplificación de Ácido Nucleico/métodos , Cartilla de ADN/genética , Sensibilidad y Especificidad , Técnicas de Diagnóstico Molecular/métodos , Factores de Tiempo , FemeninoRESUMEN
INTRODUCTION: Rubella is a viral infectious disease, and humans are the only reservoir of the virus. In 2020, all WHO member countries conducted epidemiological surveillance for rubella, and almost all (99%) had access to rubella testing at laboratories operating under the WHO Global Measles and Rubella Laboratory Network. OBJECTIVES: The aim of this study was to evaluate epidemiological indicators of rubella in Poland in 2021 compared to previous years, taking into account the impact of the COVID-19 pandemic. MATERIAL AND METHODS: The assessment of the epidemiological situation was based on a review of data from the bulletin , "Infectious Diseases and Poisons in Poland in 2021" (5), and the assessment of the immunization status of the population was based on data from the bulletin , "Immunization in Poland in 2021" (6). Classification of cases was made based on the definition used in the 2021 surveillance (7). Data from the epidemiological surveillance system "EpiBase" were also used. RESULTS: In 2021, 50 cases of rubella were registered, 48 fewer than in 2020 (98 cases). There was also a decrease in incidence to 0.13 per 100,000, compared to 0.26 per 100,000 in 2020. The highest incidence, regardless of gender and residential environment, was recorded in the 0-4 age group (1.23 per 100 thousand). No cases of congenital rubella syndrome were reported in 2021. CONCLUSIONS: In 2021, there was a decrease in the number of rubella cases in Poland, which could be a result of the COVID-19 pandemic and the introduced restrictions. In addition, rubella was registered 99% on the basis of clinical diagnoses, without the required laboratory confirmation, which means that other rash diseases could be registered as rubella.
Asunto(s)
COVID-19 , Rubéola (Sarampión Alemán) , Humanos , Rubéola (Sarampión Alemán)/epidemiología , Rubéola (Sarampión Alemán)/prevención & control , Polonia/epidemiología , Femenino , Masculino , Adolescente , Niño , Adulto , Preescolar , Lactante , COVID-19/epidemiología , Incidencia , Adulto Joven , Persona de Mediana Edad , Recién Nacido , Distribución por Edad , SARS-CoV-2 , Sistema de Registros , Distribución por Sexo , Población Urbana/estadística & datos numéricos , Vacuna contra la Rubéola/uso terapéuticoRESUMEN
Introduction: Homeless individuals suffer a high burden of vaccine-preventable infectious diseases. Moreover, they are particularly susceptible to adverse infection outcomes with limited access to the health care system. Data on the seroprevalence of measles, mumps, rubella, and varicella within this cohort are missing. Methods: The seroprevalence of measles, mumps, rubella, and varicella was determined within the homeless population in Germany. Predictors of lacking immune protection were determined using multivariable logistic regression analysis. Results: Homeless individuals in Germany (n = 611) showed a seroprevalence of 88.5% (95% CI: 85.8-91.0) for measles, 83.8% (95% CI: 80.6-86.6) for mumps, 86.1% (95% CI: 83.1-88.7) for rubella, and 95.7% (95% CI 93.8-97.2) for varicella. Measles seroprevalences declined from individuals born in 1965 to individuals born in 1993, with seroprevalences not compatible with a 95% threshold in individuals born after 1980. For mumps, seroprevalences declined from individuals born in 1950 to individuals born in 1984. Here, seroprevalences were not compatible with a 92% threshold for individuals born after 1975. Seronegativity for measles, mumps and rubella was associated with age but not with gender or country of origin. Discussion: Herd immunity for measles and mumps is not achieved in this homeless cohort, while there was sufficient immune protection for rubella and varicella. Declining immune protection rates in younger individuals warrant immunization campaigns also targeting marginalized groups such as homeless individuals. Given that herd immunity thresholds are not reached for individuals born after 1980 for measles, and after 1975 for mumps, vaccination campaigns should prioritize individuals within these age groups.
Asunto(s)
Varicela , Personas con Mala Vivienda , Sarampión , Paperas , Rubéola (Sarampión Alemán) , Humanos , Masculino , Femenino , Paperas/inmunología , Paperas/epidemiología , Estudios Transversales , Alemania/epidemiología , Personas con Mala Vivienda/estadística & datos numéricos , Adulto , Sarampión/epidemiología , Sarampión/inmunología , Rubéola (Sarampión Alemán)/inmunología , Rubéola (Sarampión Alemán)/epidemiología , Estudios Seroepidemiológicos , Persona de Mediana Edad , Varicela/epidemiología , Varicela/inmunología , Adulto Joven , Vacunación/estadística & datos numéricos , Adolescente , AncianoRESUMEN
This study examined the association of socio-economic factors and the structure of primary care centres (PCCs) with measles, mumps, and rubella (MMR) vaccination coverage among the 8-year-old population in Catalonia, Spain. We conducted an ecological study to retrospectively assess the MMR vaccination-recorded status of children born in 2012, using public health data extracted in December 2020. For each of 300 PCCs serving 70,498 children, we calculated vaccination coverage rates from electronic health records and linked these rates to a composite deprivation index corresponding to the territory served by each PCC. We identified a relationship between unfavourable socio-economic factors and higher recorded vaccination coverage. On average, directly managed PCCs had higher vaccination coverage rates than indirectly managed PCCs. Greater utilisation of primary care services by the population was also associated with higher vaccination coverage rates. Further research is needed to generate knowledge valuable for informing more equitable child-vaccination service delivery models.
Asunto(s)
Vacuna contra el Sarampión-Parotiditis-Rubéola , Atención Primaria de Salud , Factores Socioeconómicos , Cobertura de Vacunación , Humanos , España , Atención Primaria de Salud/estadística & datos numéricos , Vacuna contra el Sarampión-Parotiditis-Rubéola/administración & dosificación , Niño , Cobertura de Vacunación/estadística & datos numéricos , Estudios Retrospectivos , Femenino , Masculino , Sarampión/prevención & control , Sarampión/epidemiología , Rubéola (Sarampión Alemán)/prevención & control , Paperas/prevención & control , Paperas/epidemiología , Vacunación/estadística & datos numéricosRESUMEN
Rubella is a major cause of congenital defects, and the presence of rubella infection in a pregnant woman may lead to fetal death or congenital defects known as congenital rubella syndrome(CRS). Since China has not yet established a national CRS surveillance system, the true incidence cannot be determined. To understand the disease burden and epidemiological characteristics of CRS cases in China, the article reports the first case of CRS in Quzhou, China, and conducts a retrospective analysis of related cases that have been reported in China over the past decade. Because the availability of rubella-containing vaccines (RCV) was not widespread in China before 2008, women of childbearing age born before 2008 are generally unvaccinated against RCV. Due to the lack of routine CRS monitoring and screening, CRS is underreported in China. Vaccination of nonimmune women of childbearing age with RCV and establishing a sensitive and timely case-based CRS surveillance system can accelerate the elimination of rubella and CRS.
Asunto(s)
Síndrome de Rubéola Congénita , Rubéola (Sarampión Alemán) , Embarazo , Humanos , Femenino , Lactante , Síndrome de Rubéola Congénita/epidemiología , Síndrome de Rubéola Congénita/prevención & control , Estudios Retrospectivos , Rubéola (Sarampión Alemán)/epidemiología , Rubéola (Sarampión Alemán)/prevención & control , Vacuna contra la Rubéola , Virus de la RubéolaRESUMEN
Rubella virus-associated granulomas commonly occur in immunocompromised individuals, exhibiting a diverse range of clinical presentations. These manifestations can vary from predominantly superficial cutaneous plaques or nonulcerative nodules to more severe deep ulcerative lesions, often accompanied by extensive necrosis and significant tissue destruction. TAP1 deficiency, an exceedingly rare primary immune-deficiency disorder, presents with severe chronic sino-pulmonary infection and cutaneous granulomas. This report highlights the occurrence of rubella virus-associated cutaneous granulomas in patients with TAP1 deficiency. Notably, the pathogenic mutation responsible for TAP1 deficiency stems from a novel genetic alteration that has not been previously reported. This novel observation holds potential significance for the field of diagnosis and investigative efforts in the context of immunodeficiency disorders.
Asunto(s)
Transportador de Casetes de Unión a ATP, Subfamilia B, Miembro 2 , Granuloma , Virus de la Rubéola , Humanos , Granuloma/etiología , Granuloma/virología , Virus de la Rubéola/genética , Transportador de Casetes de Unión a ATP, Subfamilia B, Miembro 2/deficiencia , Transportador de Casetes de Unión a ATP, Subfamilia B, Miembro 2/genética , Rubéola (Sarampión Alemán)/diagnóstico , Rubéola (Sarampión Alemán)/inmunología , Rubéola (Sarampión Alemán)/complicaciones , Masculino , Mutación , Adulto , Enfermedades de la Piel/etiología , Enfermedades de la Piel/virología , Femenino , Piel/patología , Piel/virologíaRESUMEN
BACKGROUND: Rubella remains a public health challenge in Japan, impeding the attainment of herd immunity. Despite vaccination efforts since 1976, persistent outbreaks reveal a susceptibility gap in male adults born before 1995. Seroepidemiological surveys are pivotal in evaluating population immunity and identifying at-risk groups. METHODS: This study aims to pinpoint high-risk areas for potential rubella outbreaks in Japan by merging seroepidemiological data from 2020 with population census information. Various data sources, including spatial demographic data, reported rubella and congenital rubella syndrome (CRS) cases, and traveler lodging statistics, were employed. Geospatial information for Japan's 230,300 small geographic areas was analyzed, and HI (hemagglutination inhibition) titers were examined by age and sex. Seroconversion was defined as an HI titer ≥ 1:32 or 1:16, indicating protective immunity. Geospatial maps illustrated the distribution of susceptible individuals per square kilometer, emphasizing high-risk urban areas like Tokyo and Osaka. Demographic shifts in the working-age population were assessed. RESULTS: Susceptible individuals cluster in densely populated urban centers, persisting despite demographic changes. The study highlights areas at risk of increased susceptibility, particularly with an HI titer cut-off of 1:16. Foreign travelers pose potential rubella importation risks as travel volume to Japan rises. To prevent epidemics and congenital rubella syndrome burden, achieving and sustaining herd immunity in high-risk areas is crucial. CONCLUSIONS: This study offers a comprehensive assessment of vulnerability in densely populated Japanese regions. Integrating population statistics with seroepidemiological data enhances our understanding of population immunity, guiding resource allocation for supplementary vaccination planning. To avert rubella epidemics, high-risk locations must bolster indirect protection through herd immunity, ultimately preventing congenital rubella syndrome.